Pharma Focus Asia

Papyrus Therapeutics Inc. Signs Research Collaboration With Oxford Biomedica

Friday, September 18, 2020

Papyrus Therapeutics, Inc., an emerging biopharma company developing novel extracellular tumor suppressor therapies for the treatment of cancer and Oxford Biomedica plc (LSE:OXB or the “Group”), a leading gene and cell therapy group, announced today the signing of a research collaboration agreement.

The collaboration includes the assessment of the impact and therapeutic benefit of Papyrus’ PYTX-002, a potential first-in-class gene replacement therapy that will confer ‘cellular pharmacy’ properties on a CAR-T cell therapy developed by Oxford Biomedica, initially in preclinical in vivo models of solid tumors.

The Oxford Biomedica lentiviral platform technology was used in the first FDA and EMA approved CAR-T cell therapy - Kymriah™ (tisagenlecleucel). The Group’s lead CAR-T immunotherapy candidate, OXB-302, is a lentiviral CAR-T product targeting the 5T4 antigen expressed on the cell surface of many solid cancers.

“We are very pleased to have the opportunity to collaborate with Oxford Biomedica on the development on a CAR-T product candidate incorporating PYTX-002. This collaboration highlights the potential utility and versatility of the Company’s technology as a monotherapy as well as in combination with other treatment modalities as an effective cancer therapeutic in areas of high unmet medical need,” said Co-Founder and Chief Executive Officer Dr. Paul Blake.

Papyrus Co-Founder and Chief Scientific Adviser Professor Hani Gabra said, “Bringing together Papyrus’ technology that targets cancer through tumor suppressor replacement and conditions the microenvironment to promote activation of CAR-T therapy simultaneously provides a potentially synergistic reprogramming of the tumor and its microenvironment to leverage CAR-T therapy.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024